Acute Kidney Injury from Mononuclear Cell-Predominated Interstitial Nephritis After Introduction of a Glucagon-Like Peptide-1 Receptor Agonist: A Case Report.

Itsathitpaisarn R, Suksawad N, Wongwikrom W, Surintrspanont J, Thongsricome T

The American journal of case reports7 Dec 2025

PMID41353763PMCIDPMC12750940DOI10.12659/ajcr.949913PepBankPUB-41353763

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanCase report or seriesSafety outcome
In a woman with diabetic kidney disease, serum creatinine increased and then doubled after dulaglutide initiation.
In plain wordsA woman with diabetic kidney disease had increased creatinine after dulaglutide initiation compared with before treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseSerum creatinine
Study
n = 1
Comparator
Before dulaglutide
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.75 mg/week · subcutaneousAs given in this study (human).
Source sentences
Summary
Serum creatinine at 2-month follow-up increased and then doubled despite reduction in the azilsartan dose.
1 context sentence(design, population, supporting numbers)
Summary · context
CASE REPORT A 63-year-old woman with stage 3b diabetic kidney disease and depressive disorder was prescribed dulaglutide 0.75 mg/week subcutaneously in August 2023 due to persistent albuminuria despite receiving the maximum tolerated dose of azilsartan.
Report a problemFND-4135376301
02HumanCase report or seriesSafety outcome
A woman with diabetic kidney disease developed biopsy-confirmed active interstitial nephritis after dulaglutide initiation.
In plain wordsA woman with diabetic kidney disease developed kidney inflammation after dulaglutide initiation.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableInterstitial nephritis
Study
n = 1
Outcome group
Kidney function · Kidney and urinary
Studied dose
0.75 mg/week · subcutaneousAs given in this study (human).
Source sentences
Summary
Kidney biopsy revealed active interstitial nephritis and diabetic nephropathy without accumulation of immune complex.
2 context sentences(design, population, supporting numbers)
Summary · context
We report a case of a patient with DKD who developed an episode of interstitial nephritis after dulaglutide administration.
Summary · context
CASE REPORT A 63-year-old woman with stage 3b diabetic kidney disease and depressive disorder was prescribed dulaglutide 0.75 mg/week subcutaneously in August 2023 due to persistent albuminuria despite receiving the maximum tolerated dose of azilsartan.
Report a problemFND-4135376302
03HumanCase report or seriesSafety outcome
In a woman with diabetic kidney disease, kidney function almost completely recovered after dulaglutide withdrawal without steroids.
In plain wordsA woman's kidney function almost completely recovered after dulaglutide withdrawal compared with before withdrawal, without steroids.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseKidney function after withdrawal
Study
n = 1
Comparator
Before withdrawal
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
After discontinuing dulaglutide, there was an almost complete recovery of kidney function without steroid therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
CASE REPORT A 63-year-old woman with stage 3b diabetic kidney disease and depressive disorder was prescribed dulaglutide 0.75 mg/week subcutaneously in August 2023 due to persistent albuminuria despite receiving the maximum tolerated dose of azilsartan.
Report a problemFND-4135376303

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.